Abbott Laboratories vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
7.1
Buy
Overall
7.3
Buy
Quality
Health
Growth
Valuation
Sentiment
ABT
Analysts see 31% upside to $118.64 consensus target.
⚠ earnings contracting 20% year-over-year.
MRK
High-quality business with 37% return on equity and 28% profit margins.
⚠ earnings contracting 19% year-over-year.
Analyst Consensus
BUY
Target $118.64 (+31.0%)
25 analysts
BUY
Target $129.74 (+17.5%)
27 analysts
Fundamentals
ABT
MRK
25.4×
Trailing P/E
15.2×
14.9×
Forward P/E
11.4×
13.9%
Profit Margin
28.1%
56.5%
Gross Margin
77.2%
—
ROE
36.9%
7.8%
Revenue Growth
5.0%
-19.7%
Earnings Growth
-19.3%
0.78
Beta
0.28
—
Price / Book
—
$157.4B
Market Cap
$272.8B
$90 – $139
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.